FCCC LOGO Faculty Publications
Jain A , Ryan PD , Seiden MV
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location
J Natl Compr Canc Netw. 2012 Sep 1;10(9) :1076-80
PMID: 22956806   
Back to previous list
Abstract
Approximately 22,000 cases of ovarian cancer occur each year in the United States, and likely fewer than 2000 cases of mucinous ovarian cancers. Although 90% of patients with mucinous ovarian cancer present with stage I disease and have curative surgeries, advanced-stage disease is known to have a poor response to standard platinum- and taxane-based chemotherapy. Despite limited enthusiasm, standard chemotherapy is still recommended for most patients with advanced-stage mucinous malignancies of the ovary. This report presents an unusual case of a woman with HER2-positive metastatic mucinous carcinoma of the ovary treated with chemotherapy regimens typically used for colorectal malignancies, followed by epidermal growth factor receptor-targeted therapies.
Notes
Jain, Angela Ryan, Paula D Seiden, Michael V United States Journal of the National Comprehensive Cancer Network : JNCCN J Natl Compr Canc Netw. 2012 Sep 1;10(9):1076-80.